Neumora Therapeutics (NMRA) Debt Ratio (2025 - 2026)

Neumora Therapeutics (NMRA) recorded quarterly Debt Ratio of 0.34 in Q1 2026, up 20.58% quarter-over-quarter from 0.29 in Q4 2025.

Neumora Therapeutics (NMRA) Debt Ratio (2025 - 2026) Analysis & Trends

Neumora Therapeutics' Debt Ratio history runs 2 years deep, the most recent figure standing at 0.34 for Q1 2026.

In Q1 2026, Debt Ratio changed N/A year-over-year to 0.34; the TTM figure through Mar 2026 stood at 0.34 (changed N/A YoY), while the FY2025 annual figure was 0.29, changed N/A from the prior year.
Debt Ratio was 0.34 for Q1 2026 at Neumora Therapeutics, up from 0.29 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.34 in Q1 2026 to a low of 0.09 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	0.18
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	-
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Neumora Therapeutics	320.17 Mn	320.17 Mn	-	0.34

Download Data